Akari Therapeutics Plc
Close on Oct 19, 2026
- Market cap
- $1.42T
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 16, 2025 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 19, 2024 | After market close | – | $0.00 | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | Before market open | – | – | – |
Press releases
Announcements Akari Therapeutics filed with the SEC
Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces ADS Ratio Change
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
Material agreement · Agreement terminated · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation January 2025 NASDAQ: AKTX akaritx.com Next-Generation Precision Bi-Functional Antibody Drug Conjugates
Regulation FD disclosure · EX-99.1 to Form 8-K
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Akari Therapeutics Announces Shareholder Approval in Connection With
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Pipeline Prioritization of the Merged Companies
Executive or director change · Other events · EX-99.1 to Form 8-K
As of and for the Years Ended December 31, 2023 and 2022
Other events · EX-99.1 to Form 8-K
Prepaid expenses and other current assets
Other events · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
Other events · EX-99.3 to Form 8-K
Akari Therapeutics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Akari Therapeutics Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
Executive or director change · Other events · EX-99.1 to Form 8-K
2023 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Akari employee communication from Rachelle Jacques:
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Akari investor email (those who have inquired in the
Material agreement · Regulation FD disclosure · EX-99.3 to Form 8-K
Announces Existing Investors Support the Company
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur
EX-99.1 to Form 6-K
Akari Therapeutics Presents Poster on Progress
EX-99.1 to Form 6-K
For The Six Month Period Ended June 30, 2023
EX-99.1 to Form 6-K
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
EX-99.3 to Form 6-K
Announces Existing Investors Support the Company
EX-99.1 to Form 6-K
Akari Therapeutics Regains Compliance with Nasdaq
EX-99.1 to Form 6-K
Akari Therapeutics Announces Establishment of
EX-99.1 to Form 6-K
Akari Therapeutics, Plc Announces ADS Ratio Change
EX-99.1 to Form 6-K
Akari Therapeutics Announces the Appointment of
EX-99.1 to Form 6-K
Akari Therapeutics Granted Nomacopan Orphan Drug Designation from
EX-99.1 to Form 6-K
Akari Therapeutics Appoints Experienced Life Sciences Executive
EX-99.1 to Form 6-K
Akari Therapeutics Provides Updates on Development of Nomacopan
EX-99.1 to Form 6-K
Akari Therapeutics Provides Update on Development of Long-Acting
EX-99.1 to Form 6-K
Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation
EX-99.1 to Form 6-K
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad
EX-99.1 to Form 6-K